Insulet Corporation (PODD)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Insulet Corporation (PODD)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
Key Insights
Critical company metrics and information
Share Price
$272.79Market Cap
$19.13 BillionTotal Outstanding Shares
70.15 Million SharesTotal Employees
3,000Dividend
No dividendIPO Date
May 15, 2007SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.insulet.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-109.80 Million |
Net Cash Flow From Operating Activities, Continuing | $327.80 Million |
Net Cash Flow, Continuing | $213.00 Million |
Net Cash Flow From Financing Activities | $-5.00 Million |
Net Cash Flow From Investing Activities | $-109.80 Million |
Net Cash Flow From Operating Activities | $327.80 Million |
Net Cash Flow From Financing Activities, Continuing | $-5.00 Million |
Exchange Gains/Losses | $4.20 Million |
Net Cash Flow | $217.20 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Benefits Costs and Expenses | $1.69 Billion |
Selling, General, and Administrative Expenses | $869.00 Million |
Net Income/Loss Attributable To Parent | $420.90 Million |
Costs And Expenses | $1.69 Billion |
Gross Profit | $1.38 Billion |
Basic Average Shares | $70.08 Million |
Net Income/Loss | $420.90 Million |
Diluted Average Shares | $77.35 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income/Loss From Continuing Operations Before Tax | $296.70 Million |
Income/Loss From Continuing Operations After Tax | $420.90 Million |
Net Income/Loss Available To Common Stockholders, Basic | $420.90 Million |
Basic Earnings Per Share | $6.02 |
Research and Development | $201.00 Million |
Revenues | $1.98 Billion |
Income Tax Expense/Benefit | $-124.20 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Diluted Earnings Per Share | $5.87 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $306.00 Million |
Operating Expenses | $1.07 Billion |
Cost Of Revenue | $607.90 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $1.12 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Accounts Payable | $40.30 Million |
Assets | $3.03 Billion |
Current Liabilities | $506.20 Million |
Current Assets | $1.86 Billion |
Other Current Liabilities | $465.90 Million |
Liabilities And Equity | $3.03 Billion |
Other Current Assets | $1.42 Billion |
Noncurrent Assets | $1.16 Billion |
Inventory | $444.90 Million |
Noncurrent Liabilities | $1.40 Billion |
Equity | $1.12 Billion |
Liabilities | $1.91 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.